Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prapti Patel

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
American Journal of Clinical Pathology|September 4, 2020
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique EntitySharon Koorse Germans, Ozlem Kulak, Prasad Koduru, et al.
Cancers|August 27, 2021
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeFatih M Uckun, Tara L Lin, Alice S Mims, et al.
Cancers|November 13, 2021
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436Fatih M Uckun, Justin Watts, Alice S Mims, et al.
Frontiers in Oncology|January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAJustin Watts, Tara L Lin, Alice Mims, et al.
Journal of Medical Imaging and Radiation Sciences|December 14, 2022
Image-guidance triggered adaptive radiation therapy in head and neck squamous cell carcinoma: single-institution experience and implications for clinical practiceTejpal Gupta, Guncha Maheshwari, Kishore Joshi, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2021
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJason Westin, Michael B Maris, Caron A Jacobson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation TherapyVasu Tumati, Lakshya Trivedi, Hsiao-Ching Li, et al.
British Journal of Haematology|August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapyFevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.
Leukemia Research|December 7, 2020
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvementColin P Bergstrom, Saurabh Dahiya, Weina Chen, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 18, 2018
What's in a name? The heterogeneous clinical spectrum and prognostic factors in a cohort of adults with hemophagocytic lymphohistiocytosisBonnie C Prokesch, Srikanth Nagalla, Fatemeh Ezzati, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Pathology|September 4, 2020
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique EntitySharon Koorse Germans, Ozlem Kulak, Prasad Koduru, et al.
Cancers|August 27, 2021
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeFatih M Uckun, Tara L Lin, Alice S Mims, et al.
Cancers|November 13, 2021
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436Fatih M Uckun, Justin Watts, Alice S Mims, et al.
Frontiers in Oncology|January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAJustin Watts, Tara L Lin, Alice Mims, et al.
Journal of Medical Imaging and Radiation Sciences|December 14, 2022
Image-guidance triggered adaptive radiation therapy in head and neck squamous cell carcinoma: single-institution experience and implications for clinical practiceTejpal Gupta, Guncha Maheshwari, Kishore Joshi, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2021
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJason Westin, Michael B Maris, Caron A Jacobson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation TherapyVasu Tumati, Lakshya Trivedi, Hsiao-Ching Li, et al.
British Journal of Haematology|August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapyFevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.
Leukemia Research|December 7, 2020
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvementColin P Bergstrom, Saurabh Dahiya, Weina Chen, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 18, 2018
What's in a name? The heterogeneous clinical spectrum and prognostic factors in a cohort of adults with hemophagocytic lymphohistiocytosisBonnie C Prokesch, Srikanth Nagalla, Fatemeh Ezzati, et al.
Pageof 4